Navigation Links
ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
Date:2/9/2009

FREDERICK, Md., Feb. 9 /PRNewswire/ -- ImQuest Life Sciences today presented important new results on the continued development of their small molecule inhibitor of HIV-1 at the 16th CROI meeting held this week in Montreal. The presentation highlighted the advanced development of ImQuest's lead HIV pyrimidinedione inhibitor, IQP-0410. The pyrimidinediones are highly potent inhibitors of HIV, exhibiting a dual mechanism of action which includes targeting virus entry and reverse transcription. The data presented demonstrate that IQP-0410 is well tolerated and safe with plasma drug concentrations 10-20-fold greater than those required for complete suppression of HIV replication at 24-hours following oral administration. Thus, IQP-0410 can be dosed once per day, and possesses a highly positive safety profile which suggests it will be amenable for use in women of child bearing years. Nick Kaludov, Ph.D., Director of Scientific Operations presented the new findings which also included metabolism, safety pharmacology, and genotoxicology evaluations. The studies included ImQuest co-authors Karen Watson, M.S. and Robert W. Buckheit, Jr., Ph.D.

"The data presented today indicate that IQP-0410 may represent a next generation HIV drug with a highly unique mechanism of action and an excellent safety profile," said Dr. Buckheit, Executive Vice President and Chief Scientific Officer. "We look forward to our upcoming clinical trial and believe that IQP-0410 will be an attractive new addition to existing antiretroviral therapies for HIV infection."

ImQuest recently submitted an Investigational New Drug application to the FDA to initiate human clinical trials with IQP-0410 and is concurrently developing a new generation pyrimidinedione with an enhanced barrier to resistance from among the series of pyrimidinediones.

ImQuest Life Sciences (www.ImquestLS.com), a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences (www.Imquest.com), also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry.

    For further information regarding this press release please contact:
    Robert W. Buckheit, Jr., Ph.D.
    Executive Vice President and Chief Scientific Officer
    ImQuest Life Sciences, Inc.
    301-696-0274
    rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest Life Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
2. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
3. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
8. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
9. Arpida Presents Preclinical Data on AR-2474 at ICAAC
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Israel , March 27, 2017 DarioHealth ... with mobile health and big data solutions, today announced ... party insurance coverage option for U.S. consumers who want ... DarioHealth has signed strategic alliance agreements with ... verify insurance coverage benefits, and if approved, will supply ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... (hESC) Research - Global Strategic Business Report" report to their ... This ... Research in US$ Million. Annual estimates and forecasts are provided for ... from primary and secondary research. The report profiles ...
(Date:3/24/2017)... -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with ... today announced participation at the following conferences: ... Maidstone Life Sciences conference "Cancer Immunotherapy Conference" at the ... York, NY . Agenus will participate in three ... Robert B. Stein , M.D., Ph.D., President, R&D ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
Breaking Biology Technology:
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/13/2017)... 2017  RSA Conference -- RSA, a Dell Technologies ... to enhance fraud detection and investigation across digital ... Fraud & Risk Intelligence Suite. The new platform ... insights from internal and external sources as well ... customers from targeted cybercrime attacks. "Fraudsters ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
Breaking Biology News(10 mins):